Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.
Chapple C, Khullar V, Nitti VW, Frankel J, Herschorn S, Kaper M, Blauwet MB, Siddiqui E. Chapple C, et al. Among authors: siddiqui e. Eur Urol. 2015 Jan;67(1):11-14. doi: 10.1016/j.eururo.2014.06.052. Epub 2014 Aug 2. Eur Urol. 2015. PMID: 25092537 Clinical Trial.
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.
Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE. Nitti VW, et al. Among authors: siddiqui e. Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21. Int J Clin Pract. 2013. PMID: 23692526 Free PMC article.
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
Batista JE, Kölbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, Coppell A, Kaper M, Huang M, Siddiqui E; BEYOND study group. Batista JE, et al. Among authors: siddiqui e. Ther Adv Urol. 2015 Aug;7(4):167-79. doi: 10.1177/1756287215589250. Ther Adv Urol. 2015. PMID: 26445596 Free PMC article.
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Drake MJ, et al. Among authors: siddiqui e. Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8. Eur Urol. 2016. PMID: 26965560 Free article. Clinical Trial.
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Hemsted C, Nazir J, Hakimi Z, Drake MJ; BESIDE Investigators. MacDiarmid S, et al. Among authors: siddiqui e. J Urol. 2016 Sep;196(3):809-18. doi: 10.1016/j.juro.2016.03.174. Epub 2016 Apr 8. J Urol. 2016. PMID: 27063854 Clinical Trial.
156 results